glp 1 drugs and antidepressants interactions with Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes GLP-1 Receptor Agonists in Mood

Decotiis Explains Overcoming barriers Oral delivery of GLP-1 therapies is advancing through two complementary strategies that aim to overcome low gastric stability and poor epithelial uptake

If you have type 2 diabetes, Ozempic might give you the dual benefit of better blood sugar control and weight loss

Prespecified outcomes The primary outcome is all-cause mortality

MEDI0382, a GLP/glucagon receptor dual agonist, significantly reduces hepatic fat content in subjects with type 2 diabetes mellitus

While real-world results may be slightly less, the improvements go beyond weight: Lower blood sugar, blood pressure, and triglycerides Reduced waist circumference and sleep apnea symptoms Better health-related quality of life Fewer major cardiovascular events Reduced progression of fatty liver disease and chronic kidney diseaseeven in the absence of weight loss (Mozaffarian et al., 2025)

Summary Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world